What was Johnson & Johnson's overall financial performance for the third quarter of 2005?

Johnson & Johnson reported a solid third quarter in 2005 with worldwide sales reaching $12.3 billion, a 6.6% increase compared to the same period in the previous year. Net earnings rose to $2.6 billion, or $0.87 per diluted share, reflecting overall business strength despite some segment-specific challenges.

How did the different business segments perform?

The Medical Devices and Diagnostics segment was a strong performer, with sales up 14.3%, driven by notable growth in the Cordis franchise (particularly the CYPHER stent) and DePuy's orthopaedic products. The Consumer segment also saw healthy growth of 10.2%, boosted by its OTC Pharmaceutical & Nutritional, Skin Care, and Baby & Kids Care lines. The Pharmaceutical segment experienced a slight 0.5% decrease in sales, largely due to generic competition impacting products like DURAGESIC, though key drugs such as RISPERDAL and REMICADE continued to perform well.

What is the status of the proposed Guidant acquisition?

The filing indicates that Johnson & Johnson received conditional approval from the FTC for the Guidant acquisition, contingent on divesting certain assets. However, the company acknowledges serious concerns regarding Guidant's product recalls and regulatory issues, which have materially adversely affected Guidant's outlook. Consequently, Johnson & Johnson believes it is not obligated to close the acquisition under the current merger agreement terms. Guidant has filed a lawsuit seeking to compel the acquisition.

Are there any significant legal proceedings that could impact the company?

Johnson & Johnson is involved in various legal proceedings, including patent litigations related to its stent products and other medical devices, as well as lawsuits concerning drug pricing (AWP litigation) and alleged marketing practices. The company is also facing a lawsuit from Guidant regarding the acquisition. While the ultimate liability cannot be estimated with certainty, management believes that the outcomes of these proceedings, net of accrued liabilities, are not expected to have a material adverse effect on the company's financial position, although they could significantly impact results of operations and cash flows in any given period.

JNJ 10-Q Filed Nov 7, 2005

Summary

Johnson & Johnson's third-quarter 2005 report demonstrates continued top-line growth driven by strong performance across its diverse business segments, particularly Medical Devices & Diagnostics and Consumer. The company reported a 6.6% increase in worldwide sales to $12.3 billion, with international markets showing robust double-digit growth, partly fueled by favorable currency exchange rates. Despite some headwinds in the Pharmaceutical segment due to generic competition and R&D investments, overall net earnings rose to $2.6 billion, or $0.87 per diluted share, indicating solid profitability and effective cost management. Key operational highlights include significant sales increases in the Consumer segment, driven by OTC Pharmaceutical & Nutritional, Skin Care, and Baby & Kids Care products, and impressive growth in Medical Devices & Diagnostics, led by the Cordis franchise (especially the CYPHER stent) and DePuy's orthopaedic products. The company also continued its strategic acquisitions, further diversifying its portfolio. While facing ongoing legal proceedings and patent litigations, Johnson & Johnson maintains a strong liquidity position and continues to return value to shareholders through dividends and share repurchases, reinforcing its stability and financial health.

Key Highlights

1Worldwide sales grew 6.6% year-over-year to $12.3 billion for the third quarter, with international sales up 12.2% and US sales up 2.6%.
2Net earnings increased to $2.6 billion, or $0.87 per diluted share, compared to $2.3 billion, or $0.78 per diluted share, in the prior year's third quarter.
3The Medical Devices and Diagnostics segment showed strong growth of 14.3%, driven by Cordis (CYPHER stent) and DePuy orthopaedics.
4The Consumer segment reported a 10.2% sales increase, with notable growth in OTC Pharmaceutical & Nutritional, Skin Care, and Baby & Kids Care franchises.
5The Pharmaceutical segment experienced a slight sales decline of 0.5% due to generic competition on certain products like DURAGESIC, though key products like RISPERDAL, REMICADE, and TOPAMAX showed strong growth.
6Operating cash flow remained strong at $8.7 billion for the first nine months of 2005, consistent with the prior year.
7The company continues to invest heavily in Research & Development, with R&D expenses increasing by 24.7% for the first nine months of 2005.

JOHNSON & JOHNSON Quarterly Report for Q3 Ended Oct 2, 2005

Summary

Key Highlights

Frequently Asked Questions